CAS: 24922-02-9; Ethyl 3-Cyclopropyl-3-Oxopropanoate

相似化合物

630399-84-7 32249-35-7 72715-12-9

上下游产品

Cyclopropyl methyl ketone ethyl bromoacetate cyclopropropanecarbonitrile H-pyrimidin-4-one6-cyclopropyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one 1-phenyl-3-cyclopropyl-5-pyrazolone (Z)-2-Cyclopropanecarbonyl-3-(4-fluoro-phenyl)-acrylic acid ethyl ester 1-Cyclopropyl-3-(4-methoxy-phenyl)-propan-1-one

5-(Cyclopropylhydroxymethylidene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione 以 乙醇 用作溶剂,化学反应生成3-环丙基-3-羰基-丙酸乙酯
参考文献:发现新型二氢咪唑并噻唑衍生物作为p53-mdm2蛋白-蛋白相互作用抑制剂:合成,生物学评估和结构-活性关系
标题:发现新型二氢咪唑并噻唑衍生物作为p53-mdm2蛋白-蛋白相互作用抑制剂:合成,生物学评估和结构-活性关系
摘要:我们从nutlins作为最初的线索开始,设计并生成了双环支架,旨在将顺式-双氯苯基部分置于与mdm2可能发生疏水相互作用的等效位置.结果,我们发现了具有二氢咪唑并噻唑支架的新型mdm2抑制剂.在分子模型的辅助下,对二氢咪唑并噻唑支架上侧链的进一步研究导致化合物显示出与nutlin-3A几乎相同的体外效价.
Doi:10.1016/j.Bmcl.2012.08.086

专利信息

专利号:US-2024309003-A1
优先权日:2021-05-04
标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN; PANDYA BHAUMIK; KAPLAN ALAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2â€?). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-9242998-B2
优先权日:2013-02-07
标题 :Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C
发明人：HE SHUWEN; DAI XING; PALANI ANANDAN; NARGUND RAVI; LAI ZHONG; ZORN NICOLAS; XIAO DONG; DANG QUN; MCCOMAS CASEY C; LI PENG; PENG XUANJIA; SOLL RICHARD
权利人:HE SHUWEN; DAI XING; PALANI ANANDAN; NARGUND RAVI; LAI ZHONG; ZORN NICOLAS; XIAO DONG; DANG QUN; MCCOMAS CASEY C; LI PENG; PENG XUANJIA; SOLL RICHARD; MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

专利号:US-8952042-B2
优先权日:2009-08-19
标 题 :FXR (NR1H4) binding and activity modulating compounds
发明人：KREMOSER CLAUS; ABEL ULRICH; STEENECK CHRISTOPH; KINZEL OLAF
权利人:KREMOSER CLAUS; ABEL ULRICH; STEENECK CHRISTOPH; KINZEL OLAF; PHENEX PHARMACEUTICALS AG
摘要:The present invention relates to compounds of formula (1): n nwhere R, A, Q and Z are defined herein, or an enantiomer, diastereomer, tautomer, solvate, prodrug or pharmaceutical acceptable salt thereof. These compounds bind to the NR1H4 receptor (FXR) and act as agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.

专利号:US-11739065-B2
优先权日:2016-06-13
标题 :FXR (NR1H4) modulating compounds
发明人：BLOMGREN PETER A; CURRIE KEVIN S; GEGE CHRISTIAN; KROPF JEFFREY E; XU JIANJUN
权利人:GILEAD SCIENCES INC
摘要:The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

专利号:US-9751874-B2
优先权日:2014-12-17
标题:Hydroxy containing FXR (NR1H4) modulating compounds
发明人：GEGE CHRISTIAN; KINZEL OLAF; KREMOSER CLAUS; SCHMITT AARON C
权利人:GILEAD SCIENCES INC
摘要:The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

专利号:US-11225473-B2
优先权日:2019-01-15
标题:FXR (NR1H4) modulating compounds
发明人：BLOMGREN PETER A; CURRIE KEVIN S; FRICK MORIN MAE; HORSTMAN ELIZABETH M; KAPLAN JOSHUA A; KROPF JEFFREY E; WATKINS WILLIAM J
权利人:GILEAD SCIENCES INC
摘要:The present disclosure relates generally to compounds that bind to FXR and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.